Public Health & Health Science Division, ULAB

The goal of this literature review is to analyze various treatment options for Alzheimer’s Disease, a neurodegenerative disorder that affects many Americans. Four drugs being studied in the paper include Donepezil, Memantine, Lecanemab, and Rivastigmine. Donepezil is an acetylcholinesterase inhibitor that is used for patients with mild or moderate AD. Memantine is used to block the overflow of glutamate through NMDA receptors and to treat patients with moderate to severe AD. It can be used in combination therapy with Donepezil and Galantamine. Lecanemab is used to target amyloid-beta plaques and to reduce aggregates. Rivastigmine is a carbamate cholinesterase inhibitor that can be used to inhibit both acetylcholinesterase and butyrylcholinesterase for mild to moderate cases of AD. All four drugs have been shown to slow down the progression of AD by increasing cognitive performance and to improve the quality of life for patients and their caregivers